Catalent Publishes Fifth Annual Corporate Responsibility Report, Highlighting Progress and Reinforcing Long-Term Commitment

• Commits to reducing Scope 1 and 2 greenhouse gas emissions by 42% from its 2022 baseline by 2030, with commitment to ensuring 70% of supplier emissions have science-based targets by end of fiscal 2028.
• Implemented ISO-certified environmental management systems at 24 locations, which account for more than 70% of the company’s overall energy use.
• Continued to build social impact through increased diversity and inclusion efforts, contributions to STEM education and other important causes, and support for communities in which the company operates, with a record year for volunteering as part of its annual Month of Service.

March 7, 2024 – Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, has today published its fiscal 2023 Corporate Responsibility Report, highlighting positive progress across every pillar of Catalent’s corporate responsibility strategy – People, Environment, and Community. The report also outlines the company’s future commitments as it progresses its mission to help people lead better and healthier lives.

One area of significant progress in fiscal 2023 was Catalent’s efforts to reduce its environmental footprint and address the harmful effects of climate change. A key initiative supporting this progress was the implementation of ISO-certified environmental management systems at 24 Catalent locations, which account for more than 70% of Catalent’s overall energy use.

With new targets approved by the Science Based Targets initiative (SBTi), Catalent is committed to reducing its Scope 1 and 2 greenhouse gas (GHG) emissions by 42% by 2030 from its 2022 baseline. As part of the SBTi targets, Catalent has also committed to ensuring that 70% of supplier emissions will have science-based targets by end of fiscal 2028.

Alessandro Maselli, Catalent’s President and Chief Executive Officer, said: “Our mission to help people live better and healthier lives is made possible not only through our business, but through our actions and commitments to improve the planet and contribute more broadly to society.”

“Building on great progress in fiscal 2023, I am excited to share our expanded commitments to minimize our impact on the environment and build a better planet. I am extremely proud of our team and their ongoing work to build a diverse and inclusive working environment, and a brighter future for our people, shareholders, and the communities we serve.”

In addition to environmental performance, Catalent delivered several key initiatives throughout fiscal 2023 to help assure the quality, safety, and effectiveness of the treatments it develops, manufactures, and supplies for customers and the millions of patients who depend on them. This included the formal launch of The Catalent Way, with new leadership and a greater focus on continuous improvement to deliver consistent, reliable, and sustainable outcomes for clients, patients, and employees.

In fiscal 2023, Catalent continued its investment in cultivating a diverse and inclusive workplace, and was recognized for the second year in a row as a “Best Place to Work for People with Disabilities.”

In fiscal 2023, Catalent’s contribution to STEM education and other important causes remained close to its all-time high of $1.3 million. Catalent’s employees showed up in record numbers to give back to their communities, with colleagues volunteering in 100 projects across its communities as part of the Catalent Month of Service.

The fiscal 2023 Catalent Corporate Responsibility Report is available at catalent.com/2023-corporate-responsibility-report.

Further information can be requested by contacting corporateresponsibility@catalent.com.

NOTES FOR EDITORS

ABOUT CATALENT

Catalent, Inc. is a global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,500 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply approximately 70 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of nearly 18,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated nearly $4.3 billion in revenue in its 2023 fiscal year.

More products. Better treatments. Reliably supplied.™

Contacts

Investor Contact:
Paul Surdez
+1 (732) 537-6325
investors@catalent.com

Media Contact:
Laura Hortas
+1(609) 240-7025
media@catalent.com